Two cases showing the effects of bevacizumab on recurrent cervical cancer with pleural effusion

No abstract is available for this paper.

• Publication year

  2022

• Venue

  International Cancer Conference Journal

• Publication date

  2022-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13691-022-00538-xPMID 35669902PMCID PMC9163267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer

  2019cited by this paper
• Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score

  2018cited by this paper
• Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

  2017cited by this paper
• A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.

  2016cited by this paper
• Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.

  2016cited by this paper
• VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis

  2015cited by this paper
• Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer.

  2015cited by this paper
• Improved survival with bevacizumab in advanced cervical cancer.

  2014cited by this paper
• Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases.

  2011influential reference
• Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

  2010cited by this paper
• Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

  2010cited by this paper
• Reply to the letter: Delayed radiotherapy related effusions: Malignant or not malignant, that is the question?

  2008cited by this paper
• The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism.

  2007cited by this paper
• Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.

  2007cited by this paper
• Diagnosis and management of malignant pleural effusions

  2007cited by this paper
• The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.

  2006cited by this paper
• Malignant pleural effusion, current and evolving approaches for its diagnosis and management.

  2006cited by this paper
• Vascular Endothelial Growth Factor and Prognosis of Cervical Carcinoma

  2000cited by this paper
• Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

  1999cited by this paper
• Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer

  1999cited by this paper

• No citing papers are available for this paper.